Chinese expert consensus on multigene testing for adjuvant treatment of HR-positive, HER-2 negative early breast cancer(2023 edition).
10.3760/cma.j.cn112152-20230627-00266
- Collective Name:International Medical Society, Chinese Anti-Cancer Association;;Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Early stage;
Expert consensus;
Multigene testing
- MeSH:
Humans;
Female;
Breast Neoplasms/genetics*;
Consensus;
East Asian People;
Prognosis;
Chemotherapy, Adjuvant;
Receptor, ErbB-2/genetics*
- From:
Chinese Journal of Oncology
2023;45(10):863-870
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common malignant tumor in women, of which the majority is early breast cancer (EBC). The strategy of postoperative adjuvant treatment relies mainly on the clinicopathologic characteristics of patients, but there are certain deficiencies if only depending on it to assess treatment benefits and disease prognosis. Multigene testing tools can evaluate the prognosis and predict therapeutic effects of breast cancer patients to guide the clinical decision-making on whether to use adjuvant chemotherapy, radiotherapy, and endocrine therapy by detecting the expression levels of specific genes. The consensus-writing expert group, based on the characteristics, validation results, and accessibility of the multigene testing tools and combined with clinical practice, described the result interpretation and clinical application of OncotypeDx(®) (21-gene), Mammaprint(®) (70-gene), RecurIndex(®) (28-gene), EndoPredict(®)(12-gene), and BreastCancerIndex(®) (BCI, 7-gene) for hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC. The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help guide and standardize the clinical use of multigene testing tools and further improve the level of precise treatment for EBC.
